You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰森製藥(03692.HK)2021年純利增長約5.6%至27.13億元 末期息7.32分
格隆匯 03-29 18:59

格隆匯3月29日丨翰森製藥(03692.HK)發佈公吿,2021年,公司收入約人民幣99.35億元,同比增長約14.3%;研發開支約人民幣17.97億元,同比增長約43.5%;溢利約人民幣27.13億元,同比增長約5.6%;董事會建議派發末期股息每股人民幣7.32分。

隨着廣大民眾對於健康的意識進一步提高,以及國家醫改的持續深入,醫藥行業的發展挑戰與機遇並存。集團將堅定並加快創新發展的步伐,實現全面轉型升級。本着以患者為核心、以臨牀需求為導向的研發理念,進一步夯實自主研發能力、提升研發效率、加速創新產品落地和創新成果的轉化,持續提升集團創新藥產品的收入貢獻比重;此外,通過BD,不斷拓展、深化與全球領先藥企的合作,引進國際前沿技術和產品,豐富集團產品管線、進一步優化集團的產品結構、提升集團的持續創新能力。同時,通過保障穩定高效的生產供應,嚴格維持高品質的產品質量,持續積累並強化營銷體系建設,打造一流的商業化體系及團隊,尤其是創新藥營銷體系和隊伍的建設,不斷努力提升本集團的綜合競爭力,將更多、更好的創新產品帶給全球患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account